Brief: Knight Therapeutics Enters Into Exclusive License Agreement With Supernus Pharmaceuticals For Qelbree® (Viloxazine) In Canada

Knight Therapeutics

19/12/2023 12:33

Dec 19 (Reuters) - Knight Therapeutics Inc  GUD.TO :
    * KNIGHT THERAPEUTICS ENTERS INTO EXCLUSIVE LICENSE
AGREEMENT WITH
SUPERNUS PHARMACEUTICALS FOR QELBREE® (VILOXAZINE) IN CANADA
    * KNIGHT THERAPEUTICS INC - FINANCIAL TERMS OF AGREEMENT
WERE NOT
DISCLOSED
    * KNIGHT THERAPEUTICS INC - A SECOND PHASE 4 CLINICAL TRIAL7
IN
PRESCHOOL AGE CHILDREN WITH ADHD IS PLANNED TO COMMENCE IN
JANUARY 2024

Source text for Eikon:  ID:nGNX7fdSzT 
Further company coverage:  GUD.TO 

 ((Reuters.Briefs@thomsonreuters.com;))